With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

The FDA cited in its letter to SK several issues with the risk and benefit information presented about Xcopri in the ad. For ...

Anti-vaccine sentiment is alive and well, especially in the U.S. And it was evident in recent weeks as drugmakers revealed ...

But perhaps the larger story associated with the unsurprising result is the market reaction, as Novo's shares fell by nearly 9% at the U.S. market open Monday.

Eli Lilly is continuing its recent pattern of tying disease awareness-raising efforts to major pop cultural moments. | Eli Lilly's latest high-profile crossovers—which include a starry TV partnership ...